CY2014033I1 - Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων - Google Patents

Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων

Info

Publication number
CY2014033I1
CY2014033I1 CY2014033C CY2014033C CY2014033I1 CY 2014033 I1 CY2014033 I1 CY 2014033I1 CY 2014033 C CY2014033 C CY 2014033C CY 2014033 C CY2014033 C CY 2014033C CY 2014033 I1 CY2014033 I1 CY 2014033I1
Authority
CY
Cyprus
Prior art keywords
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
quinoline
Prior art date
Application number
CY2014033C
Other languages
English (en)
Other versions
CY2014033I2 (el
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY2014033I1 publication Critical patent/CY2014033I1/el
Publication of CY2014033I2 publication Critical patent/CY2014033I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY2014033C 2002-07-25 2014-08-14 Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων CY2014033I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
EP03771115A EP1527050B1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors
PCT/EP2003/050322 WO2004011436A1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors

Publications (2)

Publication Number Publication Date
CY2014033I1 true CY2014033I1 (el) 2016-04-13
CY2014033I2 CY2014033I2 (el) 2016-04-13

Family

ID=31188461

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20101100634T CY1111882T1 (el) 2002-07-25 2010-07-07 Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
CY20121101241T CY1113497T1 (el) 2002-07-25 2012-12-19 Παραγωγα κινολινης ως ενδιαμεσες ενωσεις σε μυκοβακτηριακους αναστολεις
CY2014033C CY2014033I2 (el) 2002-07-25 2014-08-14 Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20101100634T CY1111882T1 (el) 2002-07-25 2010-07-07 Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
CY20121101241T CY1113497T1 (el) 2002-07-25 2012-12-19 Παραγωγα κινολινης ως ενδιαμεσες ενωσεις σε μυκοβακτηριακους αναστολεις

Country Status (38)

Country Link
US (1) US7498343B2 (el)
EP (2) EP2301544B1 (el)
JP (1) JP4484703B2 (el)
KR (1) KR100733577B1 (el)
CN (2) CN101070304B (el)
AP (1) AP2421A (el)
AR (1) AR040673A1 (el)
AT (1) ATE463482T1 (el)
AU (1) AU2003262529B2 (el)
BE (1) BE2014C051I2 (el)
BR (1) BRPI0312927B8 (el)
CA (1) CA2493225C (el)
CY (3) CY1111882T1 (el)
DE (1) DE60332023D1 (el)
DK (2) DK1527050T3 (el)
EA (1) EA008937B1 (el)
ES (2) ES2395237T3 (el)
FR (1) FR14C0060I2 (el)
HK (2) HK1083496A1 (el)
HR (2) HRP20050045B1 (el)
HU (1) HUS1400047I1 (el)
IL (2) IL166457A (el)
IS (1) IS2914B (el)
LU (1) LU92520I2 (el)
ME (1) ME00131B (el)
MX (1) MXPA05001052A (el)
MY (1) MY143564A (el)
NL (1) NL300684I2 (el)
NO (2) NO329935B1 (el)
NZ (1) NZ538391A (el)
PL (1) PL222801B1 (el)
PT (2) PT1527050E (el)
RS (1) RS52431B (el)
SI (2) SI2301544T1 (el)
TW (1) TWI323730B (el)
UA (1) UA82198C2 (el)
WO (1) WO2004011436A1 (el)
ZA (1) ZA200500680B (el)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
JP4773975B2 (ja) 2004-01-23 2011-09-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換されたキノリン類およびマイコバクテリア抑制剤としてのそれらの使用
DE602005006744D1 (de) * 2004-01-29 2008-06-26 Janssen Pharmaceutica Nv Chinolinderivate zur verwendung als inhibitoren von mycobakterien
NZ550840A (en) * 2004-05-28 2010-01-29 Janssen Pharmaceutica Nv Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
US8088891B2 (en) * 2004-09-28 2012-01-03 Janssen Pharmaceutica N.V. Bacterial ATP synthase binding domain
BG66437B1 (bg) * 2004-12-24 2014-07-31 Janssen Pharmaceutica N.V. Използване на хинолинови съединения за лечение на латентна туберкулоза
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
ME01445B (me) * 2005-05-25 2013-12-20 Janssen Pharmaceutica Nv PROCES ZA PRIPREMU (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALF A-l-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
PL1898909T3 (pl) * 2005-06-28 2017-03-31 Janssen Pharmaceutica Nv Pochodne chinoliny jako środki przeciwbakteryjne
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
CA2869453C (en) 2012-04-27 2021-03-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
AU2013366572B2 (en) 2012-12-21 2018-08-30 Janssen Sciences Ireland Uc Antibacterial compounds
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CN107205945A (zh) 2015-01-27 2017-09-26 詹森药业有限公司 可分散组合物
EP3288386B1 (en) * 2015-04-29 2022-01-19 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Anti-phytopathogenic compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
EP3316968A1 (en) 2015-07-02 2018-05-09 Janssen Sciences Ireland UC Antibacterial compounds
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
KR102106318B1 (ko) * 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
WO2017149551A1 (en) * 2016-03-03 2017-09-08 Council Of Scientific & Industrial Research Substituted aurone alkaloids as anti-mycobacterial agents
JP6997095B2 (ja) * 2016-03-07 2022-02-03 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド 抗菌性化合物およびその使用
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
AU2017286370B2 (en) 2016-06-16 2021-09-09 Janssen Sciences Ireland Uc Heterocyclic compounds as antibacte rials
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
BR112022003799A2 (pt) 2019-09-13 2022-05-24 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
KR20220075335A (ko) 2019-09-30 2022-06-08 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균 화합물
JP2022550784A (ja) 2019-09-30 2022-12-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ４－キノリノン抗菌化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
PE20221725A1 (es) 2019-12-27 2022-11-04 Tecnimede Soc Tecnico Medicinal Sa Nuevos compuestos farmaceuticos
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
EP4178541A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
EP4178540A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
JP2023533014A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
WO2022194905A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20230157445A (ko) 2021-03-17 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2024000111A (es) 2021-06-29 2024-01-19 Tecnimede Soc Tecnico Medicinal Sa Compuestos heterociclicos para el tratamiento de tuberculosis.
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
TW202423427A (zh) 2022-09-28 2024-06-16 比利時商健生藥品公司 長效配方
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
KR20010014030A (ko) * 1997-06-19 2001-02-26 더글라스이.리디치 퀴놀린-인돌 항균제, 이들의 용도 및 조성물
AU6645198A (en) * 1998-01-23 1999-08-09 Fire Armour Pte Ltd Nozzle with axially and perpendicularly directed apertures
JP2002501061A (ja) * 1998-01-26 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌剤用キノリン誘導体
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
NO20050476L (no) 2005-01-27
EP2301544B1 (en) 2012-09-19
NL300684I2 (el) 2016-10-11
HRP20050045A2 (en) 2006-06-30
PT1527050E (pt) 2010-06-22
JP4484703B2 (ja) 2010-06-16
LU92520I2 (fr) 2015-11-02
CY1111882T1 (el) 2015-11-04
NO2014021I2 (el) 2014-08-20
IS2914B (is) 2014-12-15
DK2301544T3 (da) 2013-01-02
CN101070304A (zh) 2007-11-14
AP2421A (en) 2012-06-08
EA008937B1 (ru) 2007-10-26
KR20050033607A (ko) 2005-04-12
PT2301544E (pt) 2012-12-10
MEP9208A (en) 2010-06-10
ATE463482T1 (de) 2010-04-15
NO2014021I1 (no) 2014-08-20
UA82198C2 (uk) 2008-03-25
HRP20120190B1 (hr) 2017-06-02
BR0312927A (pt) 2005-07-12
IL202655A (en) 2012-04-30
BE2014C051I2 (el) 2022-08-09
EP1527050A1 (en) 2005-05-04
HRP20050045B1 (hr) 2013-09-30
CN1671667A (zh) 2005-09-21
IL166457A0 (en) 2006-01-15
SI2301544T1 (sl) 2013-01-31
HRP20120190A2 (hr) 2012-05-31
RS52431B (en) 2013-02-28
CY2014033I2 (el) 2016-04-13
TW200410939A (en) 2004-07-01
KR100733577B1 (ko) 2007-06-29
JP2006504658A (ja) 2006-02-09
AU2003262529A1 (en) 2004-02-16
EA200500257A1 (ru) 2005-06-30
NZ538391A (en) 2005-10-28
EP2301544A1 (en) 2011-03-30
ZA200500680B (en) 2006-08-30
ES2395237T3 (es) 2013-02-11
US20050148581A1 (en) 2005-07-07
AP2005003210A0 (en) 2005-03-31
AU2003262529B2 (en) 2009-11-19
CA2493225C (en) 2012-03-20
ES2343458T3 (es) 2010-08-02
IL166457A (en) 2011-10-31
BRPI0312927B8 (pt) 2021-05-25
PL375523A1 (en) 2005-11-28
SI1527050T1 (sl) 2010-08-31
US7498343B2 (en) 2009-03-03
DE60332023D1 (de) 2010-05-20
TWI323730B (en) 2010-04-21
CA2493225A1 (en) 2004-02-05
HK1083496A1 (en) 2006-07-07
MY143564A (en) 2011-05-31
AR040673A1 (es) 2005-04-13
FR14C0060I1 (el) 2014-10-10
RS20050058A (en) 2007-06-04
FR14C0060I2 (fr) 2015-11-20
WO2004011436A1 (en) 2004-02-05
NO329935B1 (no) 2011-01-24
HK1113795A1 (en) 2008-10-17
CY1113497T1 (el) 2016-06-22
CN101070304B (zh) 2011-10-26
BRPI0312927B1 (pt) 2018-07-10
CN1325475C (zh) 2007-07-11
EP1527050B1 (en) 2010-04-07
MXPA05001052A (es) 2005-04-08
HRP20120190A8 (en) 2012-07-31
PL222801B1 (pl) 2016-09-30
DK1527050T3 (da) 2010-07-19
ME00131B (me) 2010-10-10
HUS1400047I1 (hu) 2016-09-28
IS7620A (is) 2004-12-29

Similar Documents

Publication Publication Date Title
CY2014033I1 (el) Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
ATE444068T1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
ATE428423T1 (de) Aripiprazol-komplex-formulierung und verfahren
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
IS8439A (is) Nýjar kínólín afleiður
AP2006003693A0 (en) Substituted quinolines and their use as mycobacterial inhibitors
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE60311233D1 (de) Chinolinderivate
SE0201844D0 (sv) New methods and use
SE0202986D0 (sv) Naphthamide derivatives and their use
SE0202781D0 (sv) New composition and method
SE0301596D0 (sv) New methods and use
SE0202583D0 (sv) New method and composition II
SE0302031D0 (sv) New method and compositions